Molecular therapeutics: is one promiscuous drug against multiple targets better than combinations of molecule-specific drugs?

  • Carlos L. Arteaga
  • Published 2003 in
    Clinical cancer research : an official journal of…

Abstract

Two manuscripts from the same group in this issue illustrate important aspects relevant to the discovery and development of molecule-targeted therapeutics. In the first paper, Ciardiello et al. (1) report the ability of the VEGFR-2 (Flk-1 and KDR) tyrosine kinase inhibitor ZD6474 to also block activation of the EGFR. ZD6474 inhibited the growth in soft agar… (More)

Topics

Cite this paper

@article{Arteaga2003MolecularTI, title={Molecular therapeutics: is one promiscuous drug against multiple targets better than combinations of molecule-specific drugs?}, author={Carlos L. Arteaga}, journal={Clinical cancer research : an official journal of the American Association for Cancer Research}, year={2003}, volume={9 4}, pages={1231-2} }